Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Bio-Pharma Market is Expected to reach USD 703.28 Billion by 2027 at 12.5% CAGR, Says Brandessence Market Research

This image opens in the lightbox

News provided by

Brandessence Market Research And Consulting Private Limited

13 Sep, 2022, 15:08 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Sept. 13, 2022 /PRNewswire/ -- Global Bio-Pharma Market is valued at USD 274.10 Billion in 2020 and is expected to reach USD 703.28 Billion by 2027 with a CAGR of 12.5% over the forecast period.

The increasing burden of chronic diseases, growing investment in research and development, and rising number of innovations are contributing to the growth of the Global opportunity in biopharmaceuticals Market.

Bio-Pharma Market Size, Share & Trends Analysis Report By Product (Insulin, Interferon, Monoclonal Antibody, Growth, And Coagulation Factor, Vaccine, Hormone, Erythropoietin, Others), By Application (Infectious Disease, Blood Disorder, Metabolic Disease, Cardiovascular Disease, Oncology, Neurological Disease, Immunology, And Others), Based On Region, And Segment Forecasts, 2022 – 2028.

Get Sample of Report at: https://brandessenceresearch.com/requestSample/PostId/1593

Bio-pharma Market: Competitive Analysis  

Some of the major bio-pharma companies 2021 are Amgen Inc., Eli Lily and Company, Sanofi SA, Johnson and Johnson, AstraZeneca PLC, along with Pfizer Inc. The industry is one which is very competitive and also comprises of many different players. Though, the technological advancements and product innovations, the mid and small level companies are increasing their presence. The companies that hold a major share in the market are often looking to get into strategic alliances and collaborate to expand their reach considerably. 

Apart from the above Companies there are few more Companies are working in Biopharmaceuticals Market

  • AbbVie Inc.
  • Bayer
  • Bristol-Myers Squibb
  • Merck & Co. Inc.
  • Novo Nordisk
  • GlaxoSmithKline PLC
  • Takeda Pharmaceuticals

Biopharmaceuticals Market Scope  

The global bio-pharma market will see a continuous growth in the world due to the rise in the need of vaccines with new diseases coming up all over the world. The greatest impact in the industry is going to happen due to the coronavirus induced pandemic which has added a push to the overall biopharmaceutical industry. Most of the biopharmaceutical companies strived extensively for developing a vaccine against the coronavirus. Most of them were following the traditional vaccine types like the attenuated and inactivated products.  

However, there were a few who also were developed out of the protein subunit, RNA and DNA vaccines. This is a factor which is going to boost the growth of the pharmaceuticals market in the pandemic. Though, the clinical and regulatory procedures for the drug candidates for the other indications have seen a slower pace because of the priorities shifting towards the reduction of the covid 19 infections. Bio-pharma Size will increase as there is research carried on during the pandemic.  

Recent Development on Biopharmaceutical Industry Overview

Grab Holding Inc. Merged with SPAC, Valued at $40 Billion:  On May 24th, 2021; Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, and Strongbridge Biopharma plc, a global commercial-stage biopharmaceutical company focused on the development and commercialization of medicines for rare diseases have entered into a definitive agreement under which Xeris will acquire Strongbridge for stock and contingent value rights. Based on the closing price of Xeris common stock of $3.47 on May 21st, 2021, and Strongbridge's fully diluted share capital, the agreement values Strongbridge at approximately $267 million, including the maximum aggregate amount payable under the CVRs. This is an extremely compelling transaction that will result in the formation of a scalable and diversified biopharmaceutical firm that will be more focused on specialty and rare disease therapies, preparing them for long-term product development and commercial success.

Biopharmaceuticals Market Segmentation Analysis 

The biggest segment in the market is the monoclonal antibodies. The reason for that is the success that they got in the therapeutics which is going to be a major growth driver in the market segment. The applications of the monoclonal antibodies include rheumatoid arthritis, cardiovascular diseases, cancer and cardiovascular diseases. The outbreak of the pandemic has created a major burden on the healthcare systems. There are researchers all over the world which have been making major efforts for coping up with this burden.  

Therefore, the antibodies which target the coronavirus has reached newer heights as various drugs have been getting approved for emergency treatment and this helps in the acute respiratory distress syndrome which was accompanying the coronavirus pandemic. Furthermore, the growth in the FDA approvals and newer product launches for different indications are going to drive this segment. There are various drugs which have been working in the direction of the growth of the market and will show a significant growth in the coming years.  

By Product:

  • Insulin
  • Interferon
  • Monoclonal antibody
  • Growth and coagulation factor
  • Vaccine
  • Hormone
  • Erythropoietin
  • others

By Application:

  • Infectious disease
  • Blood disorder
  • Metabolic Disease
  • Cardiovascular disease
  • Oncology
  • Neurological disease
  • Immunology and
  • Others

Buy this report now: https://brandessenceresearch.com/Checkout?report_id=1593

Bio-pharma Market Key Drivers 

Bio-pharma growth drivers suggest that there are reports that there were many new cancer cases diagnosed all over the world and there were many deaths due to the cancers. Further, there is data from the United States which suggests that the growth in the geriatric population of the world is going to see the need for different diseases to be countered in the world and this is going to be a major growth driver in the market and is going to help the market grow continuously.  

Bio-pharma Market Key Trends  

Bio-pharma trends also suggest that there is a considerable demand for the biopharmaceuticals which is accentuated by the acceleration in focus of the research and development related investments. In the last few years, the global spending on the research and development has been reaching a high and that is going to drive the market overall. The capability of the industry to treat the conditions which were considered to be untreatable earlier is going to grow the market. The market is going to be showing innovation in the coming few years too. There is also a demand which is increasing as there is a need for circumventing the side effects that are associated with some of the small-molecule therapeutics and also invasive surgical treatments.  

There are however stringent regulations as well as high investments required for the development of the biopharma drugs which are going to limit the studied market. Bio-pharma growth trends however have been given an incredible boost from the coronavirus pandemic and the investments that have been made into the industry that is going to drive the growth of this market. Bio-pharma 2022 looks very positive as the market is going to see investment from different corners. 

Get Methodology at https://brandessenceresearch.com/requestMethodology/PostId/1593

Bio-pharma Market Regional Analysis 

Bio-pharma market regional analysis shows that the growth in the burden of chronic diseases and the increase in investment in development and research activities in US are the biggest factors which are driving the bio-pharma market in the North American region. The US has been recognized as being the global capital for the innovation in the world of the life sciences. There are many investments taking place in the early stage of these companies. There was a further surge in the investments with the coronavirus related illnesses expected to boost the market of North America. There were clinical trials taking place for the development of vaccines and drugs for the treatment of the coronavirus pandemic which will further increase the market. The United States market was one which was deeply affected by the pandemic and therefore needed investment in the clinical trials. That is how this market has been expected to show continuous growth in the coming years.  

Further, there are high instances of cancer which is going to show a growth in the market and will be seeing continuous growth in the research and development being done to look for a solution to the fatal illness. There are constant activities taking place which have been aided by investments by government as well as private players. This has been the case particularly in the North America. There will be a further growth in the market of Asia Pacific which will take place due to the growth in the number of instances and the rise in population which will aid the growth of the market in the coming years.  

On Special Requirement Bio-pharma Market Report is also available for below region:

North America

  • U.S., Canada

Europe

  • Germany, France, U.K., Italy, Spain, Sweden, Netherlands, Turkey, Switzerland, Belgium, Rest of Europe

Asia-Pacific

  • South_Korea, Japan, China, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest Of APAC

Latin America

  • Mexico, Colombia, Brazil, Argentina, Peru, Rest of Latin America

Middle East and Africa

  • Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA

Get Full Access of all Report:  https://brandessenceresearch.com/pharmaceutical/bio-pharma-market

Related Reports: 

  • Global Vaccines Market Size to Hit USD 153.49 Bn in 2028
  • Insulin Delivery Devices Market Size to hit USD 33.05 Billion in 2028
  • Active Pharmaceutical Ingredients Market Size is Projected to Exceed $284.4 Bn by 2027
  • Omega-3 Market Size is expected to reach USD 4215.7 Million by 2028 with a CAGR of 12.82%
  • Nutricosmetics Market is Expected to Reach USD 11385.6 Million by 2027 with A CAGR Of 7.82%
  • Specialty Pharmaceuticals Market Size, Share, Companies & Trends Analysis By Therapeutic Area (Oncology, Inflammatory Conditions, Multiple Sclerosis, Growth Hormone, Other Disease Conditions), By Route Of Administration (Oral, Parenteral, Transdermal), By Distribution Channel (Hospitals, Retail Pharmacies, Specialty Pharmacies, Mail Order) Based On Region, And Segment Forecasts, 2022 – 2028
  • Active Pharmaceutical Ingredients Market is expected to reach USD 284.4 Billion by 2027 with a CAGR of 6.4%
  • Pharmaceutical Excipients Market is expected to reach USD 11635.0 Million by 2027 with the CAGR of 6.1%
  • Anticoagulants Market is expected to reach USD 35.26 Billion by 2024 with the CAGR of 9.8%
  • Precision Medicine Market By Technology Type Analysis ( Big Data, Analytics, Bioinformatics, Gene Sequencing, Pharmacogenomics Companion Diagnostics, ), By Sequencing Technology Analysis ( Sequencing By Synthesis, Ion Semiconductor Sequencing, Sequencing By Legation, Pyro Sequencing, Single Molecule Real Time Sequencing, Chain Termination, Nano Pore Sequencing, ), Industry Analysis, Trends, And Forecast, 2021-2027

i-Factor: Live Market intelligence platform

I-Factor is our guaranteed seal to keep our clients ahead of the competition, always. This knowledge platform delivers real-time updates on key economic indicators, competitive landscape, changing demand, trends, customized regional insights, and more. The platform visualizes key data points to help make decision making agile, trustworthy, and holistic. Register for free trial here at https://brandessenceresearch.com/i-factor/login/userRegister

Brandessence Market Research & Consulting Pvt ltd.

Brandessence Market Research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Follow Us: Linkedin 

Contact:

Mr. Vishal Sawant 
Email:
 vishal@brandessenceresearch.com 
Email: Sales@brandessenceresearch.com 
Corporate Sales: +44-2038074155 
Asia Office: +917447409162

Logo: https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.